NASDAQ:CARA
Cara Therapeutics Stock News
$0.700
+0.0284 (+4.23%)
At Close: Apr 25, 2024
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus
11:00am, Monday, 28'th Mar 2022 GlobeNewswire Inc.
Data presented in late-breaking session at the 2022 American Academy of Dermatology (AAD) Annual Meeting Data presented in late-breaking session at the 2022 American Academy of Dermatology (AAD) Annua
Cara price target lowered at H.C. Wainwright on pricing for pruritus drug (NASDAQ:CARA)
08:04pm, Monday, 14'th Mar 2022 Seeking Alpha
Flagging potential pricing issues for the company’s pruritus therapy, Korsuva, H.C
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting
09:01pm, Tuesday, 08'th Mar 2022 GlobeNewswire Inc.
Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting
09:01pm, Tuesday, 08'th Mar 2022 GlobeNewswire
Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
03:04pm, Tuesday, 08'th Mar 2022 Benzinga
Upgrades
According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth quarter, compared to
10 Biggest Price Target Changes For Tuesday
12:04pm, Tuesday, 08'th Mar 2022 Benzinga
Raymond James cut the price target on Ciena Corporation (NYSE: CIEN) from $80 to $75. Ciena shares fell 10.9% to close at $58.76 on Monday.
Telsey Advisory Group cut Capri Holdings Limited (NYSE:
Cara Therapeutics, Inc. (CARA) CEO Christopher Posner on Q4 2021 Results - Earnings Call Transcript
01:58am, Wednesday, 02'nd Mar 2022 Seeking Alpha
Cara Therapeutics down 8% after hours following Q4 2021 earnings misses
10:37pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Shares of Cara Therapeutics (CARA) are down 8% in after-hours trading after the companys Q4 2021 results missed on the top and bottom lines.
Cara Therapeutics (CARA) Reports Q4 Loss, Lags Revenue Estimates
10:15pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Cara (CARA) delivered earnings and revenue surprises of -26% and 77.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics GAAP EPS of -$0.63 misses by $0.11, revenue of $0.82M misses by $0.43M
09:08pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Cara Therapeutics press release (NASDAQ:CARA): GAAP EPS of -$0.63 misses by $0.11.Revenue of $0.82M (-99.3% Y/Y) misses by $0.43M.Shares -5.5%.
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
09:01pm, Tuesday, 01'st Mar 2022 GlobeNewswire Inc.
KORSUVA™ (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
09:01pm, Tuesday, 01'st Mar 2022 GlobeNewswire
KORSUVA™ (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed
Cara Therapeutics, Inc. (CARA) CEO Christopher Posner on Q4 2021 Results - Earnings Call Transcript
08:58pm, Tuesday, 01'st Mar 2022
Cara Therapeutics, Inc. (CARA) CEO Christopher Posner on Q4 2021 Results - Earnings Call Transcript
Cara Therapeutics (CARA) Reports Q4 Loss, Lags Revenue Estimates
06:25pm, Tuesday, 01'st Mar 2022
Cara (CARA) delivered earnings and revenue surprises of -26% and 77.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q4
02:35pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the fourth quarter of 2021.
